Nan Fung Group Holdings Ltd
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Nan Fung Group Holdings Ltd reported 38 stock positions worth $116.1 million. Its top holding was Illumina (ILMN) at 13.4% of the portfolio, followed by Harmony Biosciences (HRMY, 12.7%) and Geron (GERN, 5.4%). Compared with Q2 2024, it opened 5 new positions, sold out of 11, added to 5 and reduced 1. The biggest buy was Zai Lab Ltd.-ADR (ZLAB, shares +327%) and the biggest sale Kalvista Pharmaceuticals (KALV, shares −30%).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $116.1M (Q3 2024)
- SEC Filing
- 0001012975-24-000473 ↗ filed Nov 13, 2024
Holdings Value
Holdings 38 stocks · $116.1M
| ILMN Illumina Inc. | 13.39% | 119,196 | $15.5M | No change |
| HRMY Harmony Biosciences Holdings | 12.70% | 368,665 | $14.7M | No change |
| GERN Geron Corp. | 5.37% | 1,373,550 | $6.2M | No change |
| MRUS Merus NV | 5.17% | 120,038 | $6.0M | No change |
| ZLAB Zai Lab Ltd.-ADR | 4.89% | 235,000 | $5.7M | Add +327.3% |
| LBPH Longboard Pharmaceuticals Inc. | 4.61% | 160,570 | $5.4M | Add +11.1% |
| OCS Oculis Holding AG | 4.61% | 436,378 | $5.3M | No change |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 4.45% | 23,022 | $5.2M | No change |
| INCY Incyte Corp. | 4.22% | 74,022 | $4.9M | No change |
| XENE Xenon Pharmaceuticals Inc. | 3.62% | 106,680 | $4.2M | No change |
| EXAI Exscientia Ltd. | 3.62% | 859,892 | $4.2M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 3.56% | 106,100 | $4.1M | No change |
| TRML Tourmaline Bio Inc. | 3.25% | 146,800 | $3.8M | No change |
| LAB Standard Biotools Inc. | 3.13% | 1,883,179 | $3.6M | No change |
| SLNO Soleno Therapeutics Inc. | 2.78% | 63,950 | $3.2M | New |
| REPL Replimune Group Inc. | 2.72% | 287,846 | $3.2M | Add +40.5% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.22% | 49,120 | $2.6M | No change |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 2.03% | 463,654 | $2.4M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 1.78% | 9,762 | $2.1M | Add +71.8% |
| ASND Ascendis Pharma A/S | 1.75% | 13,600 | $2.0M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 1.54% | 154,522 | $1.8M | Reduce -29.5% |
| EXEL Exelixis Inc. | 1.44% | 64,200 | $1.7M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 1.36% | 102,984 | $1.6M | No change |
| RANI Rani Therapeutics Holdings Class A | 0.92% | 493,584 | $1.1M | No change |
| TRDA Entrada Therapeutics Inc. | 0.68% | 49,082 | $784K | No change |
| BMRN Biomarin Pharmaceutical Inc. | 0.65% | 10,815 | $760K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.65% | 1,166,952 | $756K | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 0.62% | 31,585 | $715K | Add +82.6% |
| BOLT PROJS HLDGS INC | 0.57% | 811,952 | $666K | New |
| KYMR Kymera Therapeutics Inc. | 0.44% | 10,875 | $515K | No change |
| RVMD Revolution Medicines Inc. | 0.29% | 7,300 | $331K | No change |
| SWTX Springworks Therapeutics Inc. | 0.21% | 7,450 | $239K | No change |
| ARGX Argenx SE - ADR | 0.20% | 430 | $233K | New |
| RARE Ultragenyx Pharmaceutical Inc. | 0.18% | 3,820 | $212K | New |
| DBV TECHNOLOGIES S A | 0.11% | 185,475 | $130K | No change |
| AFMDQ Affimed NV | 0.11% | 37,247 | $125K | No change |
| AEROVATE THERAPEUTICS INC | 0.09% | 47,936 | $100K | No change |
| ALXO Alx Oncology Holdings Inc. | 0.07% | 41,950 | $76K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| KALV Kalvista Pharmaceuticals Inc. | Reduce -29.5% | 1.54% | −1.21 |
| ATHIRA PHARMA INC | Sold out | 0.00% | −0.51 |
| PACB Pacific Biosciences of Calif | Sold out | 0.00% | −0.40 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.38 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.37 |
| GRAL Grail Inc. | Sold out | 0.00% | −0.33 |
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −0.24 |
| IMTX Immatics NV | Sold out | 0.00% | −0.19 |
| BMEA Biomea Fusion Inc. | Sold out | 0.00% | −0.19 |
| ABCL Abcellera Biologics Inc. | Sold out | 0.00% | −0.16 |
| KOD Kodiak Sciences Inc. | Sold out | 0.00% | −0.08 |
| FIBROGEN INC | Sold out | 0.00% | −0.06 |
Portfolio Buys Q2 2024 → Q3 2024
| ZLAB Zai Lab Ltd.-ADR | Add +327.3% | 4.89% | +3.87 |
| SLNO Soleno Therapeutics Inc. | New | 2.78% | +2.78 |
| CLYM Climb Bio Inc. | New | 2.03% | +2.03 |
| REPL Replimune Group Inc. | Add +40.5% | 2.72% | +0.75 |
| BOLT PROJS HLDGS INC | New | 0.57% | +0.57 |
| LBPH Longboard Pharmaceuticals Inc. | Add +11.1% | 4.61% | +0.44 |
| BCYC Bicycle Therapeutics PLC-ADR | Add +82.6% | 0.62% | +0.24 |
| ARGX Argenx SE - ADR | New | 0.20% | +0.20 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 0.18% | +0.18 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +71.8% | 1.78% | +0.09 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |